B Lymphocytes as Effector Cells in the Immunotherapy of Cancer

INTRODUCTION

A simple definition of B lymphocytes is a population of cells that express clonally diverse cell surface immunoglobulin (Ig) receptors recognizing specific antigenic epitopes [1]. The identification of serum gammaglobulin as the source of antibodies was the initiating event for the discovery of antibody-producing cells. Plasma cells were suggested as a source of antibody as early as 1948 [2]. Plasma cells represent the terminally differentiated cells along the B cell development/maturation pathway. The discovery of B cells occurred in the mid-1960s simultaneously with the identification of T cells. Max Cooper and Robert Good described the functional distinction between cells in the chicken bursa of Fabricius (B cells) responsible for antibody production and cells that required an intact thymus (T cells) for manifestation of delayed-type hypersensitivity responses [3,4]. Shortly thereafter, B cells were found to express surface Ig which could be used as markers to characterize these cells in the normal state as well as leukemic state.

Besides the role of B cells in antibody production (aka humoral immunity), B cells also mediate/regulate many other functions essential for immune homeostasis (Table I). Of significant importance is the antigen-presenting role of B cells in the initiation of T-cell immune responses [5–8]. Depending upon the model system, B cells have different requisite roles for antigen-presentation to T cells. The congenital absence of B cells leads to abnormalities within the immune system which includes a decrease in thymocyte numbers and diversity, defects within spleen dendritic cell (DC) and T-cell compartments, an absence of Peyer patch organogenesis and follicular DC networks, and an absence of macrophage subsets with decreased chemokine expression [1]. Besides their role in the development of the immune system, B cells can exert modulatory effects on the immune system by the elaboration of cytokines [9–11]. These effects can modulate T cell, DC, and antigen-presenting cell (APC) function; regulate lymphoid tissue organization and neogenesis; as well as regulate wound healing and transplanted tissue rejection. B cells can play a significant role in infection and autoimmunity as regulatory cells (Bregs) via the elaboration of suppressive cytokines, such as IL-10, TGF-β, or IL-4 [10,12,13].

Abnormalities in B cell biology has resulted in clinicopathologic conditions that underscore the important role of B cells in maintaining normal physiology. Developmental blockade of B cells can lead to significant immunodeficiencies where Ig production is impaired and susceptibility to infection is high [14–16]. Disruptions in the regulation of B-cell reactivity can result in B cells capable of producing high-affinity effector antibodies that have autoreactivity. This can result in pathological autoimmune conditions such as rheumatoid arthritis. Dominant subclones of B cells with cytogenetic/molecular genetic abnormalities can exist from all developmental stages of the B-cell lineage that give rise to leukemias and lymphomas.

B CELLS IN CANCER IMMUNOLOGY

The role played by B cells in cancer immunology is complex and somewhat controversial. Depending upon their state of activation, B cells have had divergent roles on T-cell differentiation and effector function. In tumor models, resting B cells have been reported to suppress T-cell-mediated antitumor immunity [17–24]. The mechanism by which suppression is mediated by resting B cells on the antitumor immune response is poorly understood. It appears to affect both CD4+ [20] and CD8+ [22,24] T cells. Elaboration of IL-10 by B cells [23] and interaction with Tregs (CD4+CD25+ cells) [24] have been implicated as potential mechanisms in tumor models. However, many of these studies have been performed using mice in which the immune system develops in the complete absence of B cells. These hosts are associated with a limited T-cell repertoire [25], lack...
B CELLS AS EFFECTOR CELLS IN ADOPTIVE IMMUNOTHERAPY

Recently, Li et al. [39] reported that tumor-primed B cells activated in vitro with anti-CD40 mAb and LPS-mediated tumor regression upon adoptive transfer into mice bearing either lung metastases or subcutaneous tumors [39]. These B cells were harvested from tumor-draining lymph nodes (TDLN) of donor mice that had been inoculated with tumor cells in the flanks. As shown in Figure 1, activated TDLN B cells mediated significant regression of pulmonary metastases [39]. The addition of TDLN T cells activated with anti-CD3 and anti-CD28 mAb in the adoptive transfer resulted in even greater tumor regression than either cell population alone (Fig. 1).

The observation that activated B cells alone can mediate tumor regression in the adoptive immunotherapy of solid tumors is unique. It was shown to be a consistent finding with three different tumor histologies (i.e., sarcoma, melanoma, and breast cancer) [39,40]. One potential mechanism by which activated B cells mediate tumor regression is via tumor cell cytotoxicity. Li et al. [40] found that activated TDLN B cells can cause lysis of tumor cells in vitro as measured by a standard LDH release assay. Using the 4T1 mammary carcinoma murine tumor, 4T1 TDLN B cells activated with LPS and anti-CD40 were able to lyse 4T1 tumor cells, and not irrelevant Renca (renal cell carcinoma) or TSA (mammary adenocarcinoma) tumor cells (Fig. 2). Hence, the B effector cells mediated tumor-specific cytotoxicity. This unique phenomenon was evident in the

### TABLE I. B Cell Properties

<table>
<thead>
<tr>
<th>B-cell functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibody production</td>
</tr>
<tr>
<td>Adaptive antibodies</td>
</tr>
<tr>
<td>Autoantibodies</td>
</tr>
<tr>
<td>Antigen presentation</td>
</tr>
<tr>
<td>T-cell costimulation</td>
</tr>
<tr>
<td>CD40, CD80, CD86</td>
</tr>
<tr>
<td>Cytokine production</td>
</tr>
<tr>
<td>Effector cytokines: IFN-γ, IL-6</td>
</tr>
<tr>
<td>Regulatory cytokines: IL-10, TGF-β, IL-4</td>
</tr>
</tbody>
</table>

**Physiological effects**
- Infection control
- Lymphoid tissue organogenesis
- Th1/Th2 cytokine balance
- Dendritic cell regulation
- Transplant rejection
- Tumor immunity
- Wound healing

...
B Effector Cells as Producers of Antigen-Specific Antibody

B cells have played a major role in the production of antibodies specific to tumor-associated epitopes. Antibodies have played an increasing role in therapeutic applications in the treatment of cancers mainly by blockade of receptors important to tumor proliferation. An example of this is bevacizumab (Avastin®) which is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). This antibody has been approved by the Food and Drug Administration (FDA) for the treatment of several solid malignancies (i.e., colorectal cancer, non-small lung cancer, glioblastoma, and renal cell cancer). Another example is cetuximab (Erbitux®) which is a humanized mAb that blocks the epidermal growth factor receptor (EGFR) and is used in the treatment of colorectal cancer and head and neck cancer. More recently, ipilimumab (Vervoy®) was approved for the treatment of melanoma. This humanized mAb binds to CTLA-4, a molecule on activated T lymphocytes that downregulates their function. By binding to CTLA-4, ipilimumab prevents blockade of the immune T-cell response. The list of therapeutic mAb that modulate cell function and can directly or indirectly lead to tumor regression is growing.

Antibodies can also exert antitumor effects by other means. One mechanism is by antibody-dependent cell-mediated cytotoxicity (ADCC). This involves effector cell-mediated lysis of a target cell that has been bound by a specific antibody. ADCC is mediated by natural killer cells, neutrophils, T cells, and macrophages. Lopez et al. [42] described the ability of B cells from tumor-bearing hosts, but not normal non-tumor-bearing hosts to mediate tumor lysis via ADCC. Another mechanism for tumor lysis involving antibody is known as complement-dependent cytotoxicity (CDC). Antibody by itself is ineffectual in the lysis of target cells. However, antibody of the IgM and IgG classes can activate the complement system resulting in cell lysis. Rituximab (Rituxan®) is a humanized mAb that binds to CD20 expressed on B cells. It was approved by the FDA for the treatment of refractory B-cell lymphomas and is thought to mediate B-cell antitumor effects via ADCC and CDC. Experimentally, complement-fixing tumor-specific antibodies can induce regression of established human melanoma and breast tumors as reported using in vivo models [31,32]. Furthermore, activated B effector cells have been found to produce complement-fixing antibody that can mediate CDC. As shown in Figure 4, antibody produced by activated B cells from D5 melanoma TDLN or MCA 205 sarcoma TDLN-mediated tumor-specific CDC. Both ADCC and CDC may represent additional mechanisms by which B effector cells mediate tumor regression in an adoptive immunotherapy setting.

One additional advantage of developing B effector cells from TDLN is the opportunity to identify novel tumor antigens. The specificity of antibody generated by activated B effector cells demonstrated in Figure 4 indicates the binding of antibody to unique epitopes on the tumor cell surface. This is further illustrated in Figure 5, where IgG2b antibody isolated from the supernatant of MCA 205 TDLN B cells activated with LPS and anti-CD40 was examined for binding to MCA 205, D5, and Pan-02 (pancreatic

![Fig. 3. Activated B cells induce tumor reactive T-cell responses in tumor-bearing hosts. Mice-bearing 4T1 tumor were treated with activated B cells, IL-2, or no treatment. Splenies of the mice were harvested and splenic T cells activated in vitro. These activated splenic T cells were tested for tumor reactivity by measuring IFN-γ release when mixed with irradiated tumor cells. Mice that received activated 4T1 TDLN B cells were found to have splenic T cells reactive to 4T1 tumor cells, and not to irrelevant tumor cells indicating the ability of activated B cells to present antigen to the secondary host (Li et al. [40]).](image)

![Fig. 4. Activated TDLN B cells produce antibody that can mediate complement-dependent cytotoxicity (CDC). Supernatants (Sup) from activation cultures of D5 and MCA 205 TDLN B cells were tested for their ability to mediate CDC in vitro. Pan-02 was used as an irrelevant tumor cell control. As can be seen, the supernatants contained antibodies that were able to specifically lyse the relevant tumor targets (Li et al. [39]).](image)
carcinoma) tumor cells in vitro [39]. By immunofluorescent staining, the IgG2b antibody bound only to MCA 205 tumor cells. Using immunoprecipitation techniques, antibody produced by tumor-specific B effector cells can be used to bind to lysates of the tumor cells and subsequently isolated by gel electrophoresis to identify unique bands that may represent potential tumor-associated antigens. An example of this is shown in Figure 6 where supernatants from activated D5 melanoma B effector cells was used to bind to D5, MCA 205, and Pan-02 tumor lysates, and the immune complex was run in separate gel lanes. Supernatants from activated D5 melanoma T effector cells were used as additional controls. The unique bands associated with the D5 B cell supernatant lane represent unique D5 epitopes which can be further characterized by mass spectroscopy.

SUMMARY

The role of B cells in cancer immunotherapy has been overshadowed by the interest in developing T-cell-mediated cellular responses. It is apparent that B cells can play a complementary role in the host response against tumor. An overview of how B cells can function in the therapeutic approach to cancer is depicted in Figure 7. Under appropriate conditions, B cells can mediate direct tumor cell killing independently or via antibody production. In addition, there appears to be an effective synergy between B and T cells to enhance the therapeutic efficacy of cancer immunotherapy. B cells can also exert regulatory functions via the release of cytokines. The role of these Breg cells in the host tumor environment remains to be defined.

ACKNOWLEDGMENTS

This work was supported in part by T32 CA009672, RO1 CA82529 and the Gillson Longenbaugh Foundation.

REFERENCES

Journal of Surgical Oncology